List of Excipients in Branded Drug APOMORPHINE HYDROCLORIDE

« Back to Dashboard

Generic Drugs Containing APOMORPHINE HYDROCLORIDE

Company	Ingredient	NDC	Excipient
TruPharma LLC	apomorphine hydrochloride	52817-720	BENZYL ALCOHOL
TruPharma LLC	apomorphine hydrochloride	52817-720	HYDROCHLORIC ACID
TruPharma LLC	apomorphine hydrochloride	52817-720	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in APOMORPHINE HYDROCLORIDE?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Apomorphine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Apomorphine hydrochloride is a short-acting dopamine agonist used for rapid treatment of “off” episodes in Parkinson’s disease. Its commercial value is constrained by chemical instability, injection-site reactions, nausea, complex administration, and limited chronic-use convenience. Excipient selection can create differentiated products through oxidation control, preservative reduction, improved tolerability, longer in-use stability, and alternative delivery systems.

The strongest commercial opportunities are preservative-free subcutaneous delivery, ready-to-use autoinjectors, continuous infusion systems, sublingual films with improved taste and mucosal absorption, and formulations that reduce sulfite or benzyl alcohol exposure. Excipient inventions can support formulation patents, device combination products, regulatory exclusivity and lifecycle extensions, although the underlying active ingredient is long off-patent.

What is apomorphine hydrochloride and how is it used?

Apomorphine hydrochloride is an injectable dopamine D1 and D2 receptor agonist. In the United States, subcutaneous apomorphine is approved for acute, intermittent treatment of hypomobility and “off” episodes in patients with advanced Parkinson’s disease. The drug acts rapidly but requires careful titration and antiemetic management because of nausea, vomiting, hypotension and somnolence risks. [1]

The principal U.S. dosage forms are:

Product or platform	Route	Commercial role	Key formulation issue
Apokyn	Subcutaneous injection	Rescue treatment for acute “off” episodes	Oxidation, preservatives, injection-site tolerability
Kynmobi	Sublingual film	Rapid non-injectable rescue treatment	Taste, mucosal irritation, saliva-dependent dissolution
Continuous infusion systems	Subcutaneous infusion	Longer-duration delivery under development or limited commercialization	Pump compatibility, adsorption, stability and local tolerability

Apomorphine hydrochloride is not the same as morphine and has no opioid analgesic role. The compound is chemically prone to oxidation, which can cause discoloration and potency loss. The formulation therefore requires control of pH, oxygen exposure, light, trace metals and container interaction.

What excipient properties are required for apomorphine hydrochloride?

The excipient strategy should address five primary risks: oxidation, precipitation, microbial contamination, local irritation and patient usability.

Oxidation control

Apomorphine contains a catechol structure that oxidizes readily. Oxidation may produce colored degradation products and reduce assay strength. A robust formulation normally combines:

• Acidic pH control.
• Low dissolved oxygen.
• Antioxidant protection.
• Chelation of trace metals.
• Low-permeability primary packaging.
• Light protection.
• Controlled headspace and nitrogen overlay where appropriate.

Sodium metabisulfite has historically been used as an antioxidant in injectable apomorphine products. The Apokyn label identifies sodium metabisulfite among the inactive ingredients and warns that sulfite sensitivity can cause allergic-type reactions, including anaphylactic symptoms in susceptible patients. [1]

Potential alternatives include sodium bisulfite, ascorbic acid, sodium ascorbate, glutathione or combinations of antioxidants and chelators. Each alternative creates regulatory and stability tradeoffs. Ascorbate can itself participate in complex redox chemistry, while glutathione may introduce impurity, oxidation and supply-chain considerations. A formulation that maintains stability without sulfites could support a meaningful product differentiation claim.

pH control

Apomorphine hydrochloride is generally formulated under acidic conditions to improve solubility and limit oxidation. The target pH must balance:

• Chemical stability.
• Solubility.
• Injection pain.
• Tissue tolerability.
• Compatibility with elastomers, needles and delivery devices.

A lower pH can improve chemical stability but may increase injection-site discomfort. A higher pH may improve tolerability but increase oxidation or precipitation risk. The commercial opportunity is a buffered formulation that maintains acceptable stability at a less irritating pH.

Candidate buffering systems include citrate, acetate, phosphate and tartrate buffers. Phosphate may create compatibility concerns with certain containers or precipitation risks under changing conditions. Citrate and acetate can influence local tolerability and metal interactions. A low-buffer-capacity formulation may reduce tissue irritation while maintaining pH during storage.

Chelation and trace-metal control

Trace metals can catalyze catechol oxidation. Disodium edetate and related chelators may improve stability at low concentrations. The commercial value of a chelator depends on whether it improves shelf life without increasing toxicity, extractables, injection-site reactions or regulatory complexity.

A formulation patent could claim a defined combination of apomorphine hydrochloride, antioxidant, chelator and acidic buffer. Such claims may be stronger than broad claims covering apomorphine alone because they connect a specific excipient system to measurable stability or tolerability results.

Preservatives

Multidose injectable products often require antimicrobial preservation. Benzyl alcohol has been used in injectable products but can create concerns involving local irritation, hypersensitivity and exposure in vulnerable populations. Chlorobutanol and phenol-based preservatives may produce similar tolerability and compatibility issues.

A preservative-free product could use:

• Single-dose cartridges.
• Unit-dose syringes.
• Blow-fill-seal ampoules.
• A closed transfer system.
• A sterile, disposable autoinjector.
• A refillable pump with validated in-use stability.

Removing preservatives may increase manufacturing and packaging costs, but the resulting product could command a premium in patients who experience injection-site reactions or require frequent rescue dosing.

What excipients are used in marketed apomorphine products?

Apokyn injection

Apokyn is a subcutaneous apomorphine hydrochloride injection. The product contains an acidic aqueous formulation with antioxidant protection and preservative-related excipients identified in the FDA prescribing information. The label describes sodium metabisulfite and benzyl alcohol among the inactive ingredients. [1]

The formulation’s commercial limitations include:

• Needle-based administration.
• Frequent dosing.
• Injection-site nodules or irritation.
• Need for dose titration.
• Nausea and hypotension.
• Sulfite sensitivity concerns.
• Handling requirements for multidose containers.

These limitations create opportunities for improved excipient and device combinations rather than simple API reformulation.

Kynmobi sublingual film

Kynmobi uses a sublingual film designed to deliver apomorphine through the oral mucosa. The dosage form avoids injection but introduces separate formulation problems:

• Bitter or metallic taste.
• Salivary dissolution.
• Film flexibility and mechanical strength.
• Mucosal adhesion.
• Uniform drug distribution.
• Moisture sensitivity.
• Mouth irritation.
• Manufacturing control of thin-film content uniformity.

Typical excipient classes for sublingual films include film-forming polymers, plasticizers, saliva-wetting agents, sweeteners, flavors, permeation modifiers and buffering agents. The formulation must avoid excessive saliva stimulation because swallowing can reduce the fraction absorbed through the sublingual mucosa.

The FDA-approved Kynmobi label identifies inactive ingredients in the sublingual film and provides administration instructions that require placement under the tongue until the film dissolves. [2] The product’s commercial history demonstrates that a noninjectable route can reduce one barrier while leaving adherence, tolerability and market-access challenges.

What formulation patents protect apomorphine hydrochloride?

The most commercially relevant patent categories are formulation and delivery claims rather than composition-of-matter claims for apomorphine.

Injectable formulation patents

Potential claim clusters include:

• Apomorphine hydrochloride with a defined antioxidant.
• Apomorphine with sulfite-free stabilization.
• Specific pH and buffer ranges.
• Chelator-containing formulations.
• Preservative-free multidose formulations.
• Reduced injection-site irritation.
• Extended in-use stability.
• Low-oxygen or nitrogen-filled containers.
• Compatibility with cartridges or autoinjectors.

A patent must provide more than a routine substitution of one antioxidant for another. Stronger claim scope usually requires comparative stability data, reduced degradation products, lower discoloration, improved injection tolerability or a defined shelf-life advantage.

Sublingual and buccal formulation patents

Relevant claim categories include:

• Mucoadhesive films.
• Rapid-dissolving films.
• Taste-masked apomorphine formulations.
• Specific polymer and plasticizer ratios.
• Permeation-enhancing systems.
• Films with controlled content uniformity.
• Moisture-resistant packaging.
• Reduced oral irritation.
• Dose strengths suitable for rescue treatment.

Taste masking is particularly important because apomorphine can produce a strong and unpleasant taste. Sweeteners alone may not be sufficient. Ion-pairing, complexation, polymer coating, cyclodextrins or lipid-based taste-masking systems may provide stronger technical differentiation.

Device and combination-product patents

A commercial product may obtain protection through an integrated drug-device system covering:

• Cartridge geometry.
• Dose selection.
• Needle concealment.
• Automatic priming.
• Delivery-force control.
• Occlusion detection.
• Dose confirmation.
• Pump compatibility.
• Closed-system transfer.
• Electronic adherence tracking.

Device patents do not eliminate formulation freedom-to-operate risk. A competitor can potentially design around the device while retaining the same active ingredient and delivery route.

How strong is the apomorphine hydrochloride patent estate?

The active ingredient has limited exclusivity value because apomorphine has been known and used clinically for decades. Commercial protection is more likely to depend on formulation, delivery system, manufacturing process, trademarks, regulatory exclusivity and market execution.

A practical patent-strength assessment should separate four layers:

Layer	Typical strength	Commercial significance
Active ingredient	Low	Limited ability to block generic or alternative formulations
Specific excipient system	Moderate	Can block closely replicated formulations if claims are narrow and technically supported
Delivery device	Moderate to high	May delay device substitution or support combination-product claims
Clinical method of use	Variable	Depends on claim scope, labeling and enforceability

The most defensible excipient patents should claim a defined composition linked to a measurable performance result. Examples include a specified impurity threshold after accelerated storage, a defined color limit, preserved potency after repeated withdrawals or reduced injection-site irritation in a comparative study.

When does apomorphine lose exclusivity?

Apomorphine itself is already off-patent. The relevant exclusivity question is whether a branded product has unexpired formulation, method-of-use, device or regulatory rights.

For injectable products, a generic applicant may pursue an abbreviated new drug application and certify against listed patents in the Orange Book. Patent scope may include formulation, labeling or device-related claims, depending on how the product is listed and regulated. For a sublingual film, the regulatory and patent analysis may be more complex because the dosage form, manufacturing process and pharmacokinetic profile may differ from an injectable product.

The Orange Book should be reviewed for:

• Current product listing.
• Patent numbers and expiration dates.
• Pediatric exclusivity.
• Thirty-month litigation stays.
• Delisting or expiration updates.
• Whether patents claim the drug, formulation, method of use or device.

The FDA’s Orange Book remains the controlling public source for listed patents and approved therapeutic-equivalence information. [3]

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV applicant could challenge listed patents by asserting that they are invalid, unenforceable or not infringed. The principal generic entry scenarios are:

Injectable generic

An injectable generic could compete on price while using a different antioxidant, preservative or container system. The key barriers would be:

• Demonstrating pharmaceutical equivalence.
• Matching strength and route.
• Showing comparable stability.
• Addressing container-closure compatibility.
• Managing injection-site tolerability.
• Obtaining sufficient supply of high-quality apomorphine hydrochloride.

A generic that uses a different excipient system may avoid some formulation claims but could face new stability or impurity risks.

Sublingual film generic

A film generic would face greater manufacturing complexity. Content uniformity, dose accuracy, film thickness, dissolution profile, tensile strength and packaging moisture control can create meaningful technical barriers. A competitor may seek approval through an ANDA if the regulatory requirements are met, but formulation and process differences can increase development cost.

505(b)(2) reformulation

A 505(b)(2) applicant could pursue a preservative-free injection, autoinjector, concentrated formulation, continuous infusion formulation or alternative mucosal dosage form. This pathway can support differentiated labeling and may avoid direct substitution with an existing product.

What FDA regulatory status applies to apomorphine hydrochloride products?

FDA-approved apomorphine products are prescription therapies for Parkinson’s disease. The regulatory strategy depends on whether the product is:

• A conventional injectable.
• A new delivery device using an existing formulation.
• A new excipient combination.
• A new dosage form.
• A reformulation relying partly on published literature or prior FDA findings.

For an injectable reformulation, the sponsor must establish sterility, particulate control, extractables and leachables, container closure integrity, stability and local tolerability. Antioxidant changes require degradation-product characterization and justification of the proposed shelf life.

For films, the sponsor must control:

• Uniformity of dosage units.
• Dissolution and disintegration.
• Adhesion and residence time.
• Moisture uptake.
• Mechanical properties.
• Microbial limits.
• Packaging performance.
• Taste and mucosal tolerability.

The excipient must have appropriate prior use, safety support or a regulatory justification suitable for the proposed route and exposure. A generally accepted oral excipient may require additional justification for sublingual or parenteral use.

What commercial opportunities exist for apomorphine excipients?

Preservative-free rescue injection

The clearest opportunity is a single-dose, preservative-free product with improved injection-site tolerability. The product could use an antioxidant and chelator system that avoids sulfites, with packaging designed for one-time administration.

Commercial advantages could include:

• Lower hypersensitivity concerns.
• Reduced preservative exposure.
• Easier patient positioning.
• Premium pricing.
• Compatibility with autoinjectors.
• Differentiation from multidose vials or cartridges.

Autoinjector-compatible formulation

A low-viscosity, low-particulate formulation packaged in a cartridge could support a ready-to-use autoinjector. Excipient work should focus on minimizing viscosity, foaming, oxidation during repeated mechanical stress and adsorption to device components.

Continuous subcutaneous infusion

Continuous delivery may reduce repeated rescue injections but increases exposure to pump materials and infusion-site tissue. The formulation must address:

• Extended in-use stability.
• Tubing adsorption.
• Pump reservoir compatibility.
• Microbial control.
• Low particulate formation.
• Infusion-site tolerability.

A low-concentration formulation may require larger injection volumes, while a concentrated formulation may increase local irritation. This creates room for excipient and device optimization.

Improved sublingual film

A next-generation film could target shorter dissolution time, lower bitterness, better mucosal adhesion and less oral irritation. Commercially relevant excipient technologies include:

• Stronger taste masking.
• Moisture-resistant polymer matrices.
• Rapid-wetting film systems.
• Permeation enhancement.
• Low-saliva formulations.
• Improved packaging for portable use.

Nasal and buccal delivery

Intranasal and buccal apomorphine are technically attractive because they could bypass injection and provide rapid onset. However, nasal irritation, mucociliary clearance, dose-volume limits, variable absorption and device reproducibility are material development risks. Excipients such as mucoadhesive polymers and permeation enhancers would require route-specific safety justification.

Manufacturing and supply-chain excipients

Commercial opportunity also exists in excipients that reduce manufacturing failure rates:

• Low-peroxide polymers.
• Low-metal-content water systems.
• Controlled-impurity antioxidants.
• Oxygen-scavenging packaging.
• Low-binding elastomers.
• Apomorphine-compatible lubricants and coatings.

These inputs can become supply-chain differentiators even when they are not independently patentable.

How does apomorphine compare with competing Parkinson’s rescue therapies?

Therapy	Route	Main advantage	Main limitation
Apomorphine injection	Subcutaneous	Rapid, established rescue option	Injection burden and tolerability
Apomorphine sublingual film	Sublingual	Avoids needles	Taste, oral tolerability and administration complexity
Levodopa inhalation powder	Pulmonary	Noninvasive rescue route	Pulmonary administration and device requirements
Levodopa-carbidopa intestinal gel	Enteral infusion	Continuous dopaminergic delivery	Invasive administration system
Oral levodopa rescue strategies	Oral	Familiar route	Slower and less predictable onset

Apomorphine’s competitive position depends heavily on convenience. An excipient strategy that improves stability alone may have limited market impact. A formulation that enables a simpler device, less painful administration or more predictable absorption has greater commercial value.

What geographic and manufacturing barriers affect commercialization?

The active ingredient is available from multiple pharmaceutical supply channels, but high-quality apomorphine hydrochloride requires control of oxidation, impurity profile and polymorphic or solid-state attributes. Geographic opportunities differ:

• United States: Orange Book patents, ANDA litigation and device substitution are central.
• European Union: Supplementary protection is generally less relevant for an old active ingredient, while national validation and formulation patents remain important.
• Japan: Local regulatory requirements and Parkinson’s treatment practices affect route selection.
• China and India: Cost-sensitive injectable markets may favor stable, preservative-free or multidose presentations, subject to local registration and manufacturing standards.

Manufacturing barriers are more significant for films, sterile cartridges and continuous infusion products than for conventional vials. A company with validated film casting, sterile fill-finish, low-oxygen packaging or drug-device assembly capabilities may have a stronger market position than a company with API access alone.

What licensing deals and partnership models are most relevant?

The most practical transaction structures include:

• Licensing a sulfite-free injectable formulation.
• Co-development of an autoinjector and cartridge.
• Regional rights for sublingual or buccal delivery.
• Excipient supply agreements with quality and continuity commitments.
• Device manufacturing partnerships.
• 505(b)(2) development collaborations.
• Acquisition of formulation and process patents.

A licensor should evaluate whether the patent claims cover the commercial product, whether the excipient system has reproducible scale-up data and whether the delivery device creates a meaningful switching barrier. Royalty value is likely to be higher for a product with clinical or usability differentiation than for a routine antioxidant substitution.

Key Takeaways

• Apomorphine hydrochloride is an oxidation-sensitive dopamine agonist used for rapid Parkinson’s “off” episodes.
• Sodium metabisulfite and other preservatives can stabilize injectable products but create tolerability and hypersensitivity concerns.
• The strongest excipient opportunity is a preservative-free, sulfite-free injectable system compatible with an autoinjector.
• Sublingual films require taste masking, rapid dissolution, mucosal tolerability and moisture protection.
• Formulation patents are more commercially important than old composition-of-matter rights.
• Generic and Paragraph IV risk depends on Orange Book listings, formulation claims, device claims and regulatory pathway.
• Continuous infusion, nasal delivery and buccal delivery offer lifecycle opportunities but require route-specific safety and stability data.
• Manufacturing control over oxygen, trace metals, polymers, packaging and device compatibility can create practical barriers beyond patent scope.
• The commercial winner will be the product that reduces administration burden while preserving rapid and predictable rescue treatment.

FAQs About Apomorphine Hydrochloride Excipient Strategy

Can sodium metabisulfite be removed from apomorphine injection?

Yes, but removal requires a replacement stability system and supporting data for oxidation, degradation products, shelf life, sterility and container compatibility. A sulfite-free formulation could have commercial value if it reduces hypersensitivity concerns without increasing injection pain or manufacturing complexity.

Which excipients are most important for sublingual apomorphine films?

Film-forming polymers, plasticizers, taste-masking agents, wetting agents, permeation modifiers and moisture-control excipients are central. The formulation must balance rapid dissolution with sufficient mechanical strength and dose uniformity.

Is apomorphine hydrochloride suitable for an autoinjector?

Yes. A suitable product would require low viscosity, low particulate burden, stable cartridge contact, controlled injection force and validated delivery accuracy. The formulation and device must be developed as a combination product.

Can a generic apomorphine product use different excipients?

Potentially. A generic may use different inactive ingredients if it meets applicable pharmaceutical-equivalence, safety, quality and performance requirements. Different excipients may also avoid selected formulation claims, although they can create new stability and tolerability risks.

What is the highest-value lifecycle strategy for apomorphine?

A preservative-free autoinjector or a better-tolerated sublingual film is likely to offer the clearest lifecycle value. Both approaches address the principal commercial weakness of conventional injection: the burden and tolerability of repeated rescue dosing.

References

1. U.S. Food and Drug Administration. (2023). Apokyn (apomorphine hydrochloride injection) prescribing information.
2. U.S. Food and Drug Administration. (2023). Kynmobi (apomorphine hydrochloride) sublingual film prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.